Patients with PAD treated with vorapaxar , when compared with placebo , also had a numerical reduction in peripheral revascularization procedures ( 8.1 % vs 9.0 % , P = .158 ) and a lower extremity amputation rate ( 0.9 % vs 1.5 % , P = .107 ) .